FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308382016> ?p ?o ?g. }

• W4308382016 abstract "<h3>Background</h3> AU-007 is a computationally designed monoclonal antibody that binds IL-2 on its CD25 binding epitope. AU-007 bound IL-2 (A/IL-2) cannot bind to trimeric (CD25, CD122, CD132) IL-2 receptors (IL-2R) on Tregs and vascular endothelium, but leaving IL-2’s binding to dimeric IL-2Rs (CD122, CD132) on T effector and NK cells unhindered. Therefore AU-007 redirects endogenous or exogenous IL-2 (aldesleukin) towards T effector and NK cell activation, while diminishing Treg activation and vascular leak. Unique in the IL-2 field, AU-007 can bind and redirect endogenous IL-2 generated from A/IL-2 driven T cell expansion in vivo, converting a Treg-mediated autoinhibitory loop into an immune-stimulating loop. Additionally, A/IL-2 is expected to substantially prolong the 90-minute T1/2 of IL-2, potentially allowing the use of endogenous IL-2 (as A/IL-2) alone to initiate an anti-tumor response. In non-human primates, AU-007 bound IL-2 with a similar affinity to human IL-2 and increased IL-2 serum concentrations in a dose- dependent manner while demonstrating an excellent safety profile. <h3>Methods</h3> Phase 1 of this Phase 1/2 study (<b>NCT05267626</b>) consists of 3 dose escalation arms. Each Arm begins with one 1+2 escalation cohort followed by 3+3 escalation cohorts. In Arm 1A, escalating doses of monotherapy AU-007 (Q2W) are evaluated in sequential cohorts. In Arm 1B, AU-007 (Q2W) is evaluated in combination with a single low-dose of aldesleukin with the first AU-007 dose. The AU-007 dose will be fixed with escalating aldesleukin doses in sequential cohorts. In Arm 1C, AU-007 is evaluated in combination with escalating low-doses of aldesleukin, both given Q2W. The AU-007 and aldesleukin dose and schedule for Phase 2 cohort expansion in selected solid tumor types will be based on safety, objective signs of efficacy and PD parameters including increases of IL-2 concentration (as A/IL-2), total lymphocytes, CD8+ T cells, IFN-γ, and soluble CD25. <h3>Results</h3> As of July 2022, two patients enrolled into dose escalation Arm 1A, 1 patient on 0.5 mg/kg (First In Human starting dose) and one patient into the second cohort (1.5 mg/kg). AU-007 was well tolerated with no drug related adverse events in the ongoing dose escalation. <h3>Conclusions</h3> At this early data cut, AU-007 monotherapy given 0.5 mg/kg Q2W or 1.5 mg/kg Q2W was safe and well tolerated. Data from additional patients are expected to be presented in the poster. <h3>Trial Registration</h3> NCT05267626 <h3>Ethics Approval</h3> HREC: Monash Health Human Research Ethics Committee CT-2021-CTN-03938-1 All of the participants in this study gave informed consent before taking part in the study." @default.
• W4308382016 created "2022-11-11" @default.
• W4308382016 creator A5008701409 @default.
• W4308382016 creator A5011751578 @default.
• W4308382016 creator A5024421938 @default.
• W4308382016 creator A5032731817 @default.
• W4308382016 creator A5044715236 @default.
• W4308382016 creator A5049181098 @default.
• W4308382016 creator A5063132730 @default.
• W4308382016 creator A5064660108 @default.
• W4308382016 creator A5065022271 @default.
• W4308382016 creator A5082218764 @default.
• W4308382016 date "2022-11-01" @default.
• W4308382016 modified "2023-09-25" @default.
• W4308382016 title "775 Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors" @default.
• W4308382016 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0775" @default.
• W4308382016 hasPublicationYear "2022" @default.
• W4308382016 type Work @default.
• W4308382016 citedByCount "0" @default.
• W4308382016 crossrefType "proceedings-article" @default.
• W4308382016 hasAuthorship W4308382016A5008701409 @default.
• W4308382016 hasAuthorship W4308382016A5011751578 @default.
• W4308382016 hasAuthorship W4308382016A5024421938 @default.
• W4308382016 hasAuthorship W4308382016A5032731817 @default.
• W4308382016 hasAuthorship W4308382016A5044715236 @default.
• W4308382016 hasAuthorship W4308382016A5049181098 @default.
• W4308382016 hasAuthorship W4308382016A5063132730 @default.
• W4308382016 hasAuthorship W4308382016A5064660108 @default.
• W4308382016 hasAuthorship W4308382016A5065022271 @default.
• W4308382016 hasAuthorship W4308382016A5082218764 @default.
• W4308382016 hasBestOaLocation W43083820161 @default.
• W4308382016 hasConcept C134018914 @default.
• W4308382016 hasConcept C153911025 @default.
• W4308382016 hasConcept C159654299 @default.
• W4308382016 hasConcept C16613235 @default.
• W4308382016 hasConcept C170493617 @default.
• W4308382016 hasConcept C185592680 @default.
• W4308382016 hasConcept C195616568 @default.
• W4308382016 hasConcept C203014093 @default.
• W4308382016 hasConcept C2776090121 @default.
• W4308382016 hasConcept C2777371288 @default.
• W4308382016 hasConcept C502942594 @default.
• W4308382016 hasConcept C51785407 @default.
• W4308382016 hasConcept C542903549 @default.
• W4308382016 hasConcept C55493867 @default.
• W4308382016 hasConcept C79484868 @default.
• W4308382016 hasConcept C86803240 @default.
• W4308382016 hasConcept C8891405 @default.
• W4308382016 hasConcept C95444343 @default.
• W4308382016 hasConceptScore W4308382016C134018914 @default.
• W4308382016 hasConceptScore W4308382016C153911025 @default.
• W4308382016 hasConceptScore W4308382016C159654299 @default.
• W4308382016 hasConceptScore W4308382016C16613235 @default.
• W4308382016 hasConceptScore W4308382016C170493617 @default.
• W4308382016 hasConceptScore W4308382016C185592680 @default.
• W4308382016 hasConceptScore W4308382016C195616568 @default.
• W4308382016 hasConceptScore W4308382016C203014093 @default.
• W4308382016 hasConceptScore W4308382016C2776090121 @default.
• W4308382016 hasConceptScore W4308382016C2777371288 @default.
• W4308382016 hasConceptScore W4308382016C502942594 @default.
• W4308382016 hasConceptScore W4308382016C51785407 @default.
• W4308382016 hasConceptScore W4308382016C542903549 @default.
• W4308382016 hasConceptScore W4308382016C55493867 @default.
• W4308382016 hasConceptScore W4308382016C79484868 @default.
• W4308382016 hasConceptScore W4308382016C86803240 @default.
• W4308382016 hasConceptScore W4308382016C8891405 @default.
• W4308382016 hasConceptScore W4308382016C95444343 @default.
• W4308382016 hasLocation W43083820161 @default.
• W4308382016 hasOpenAccess W4308382016 @default.
• W4308382016 hasPrimaryLocation W43083820161 @default.
• W4308382016 hasRelatedWork W1981898410 @default.
• W4308382016 hasRelatedWork W2045916887 @default.
• W4308382016 hasRelatedWork W2059293789 @default.
• W4308382016 hasRelatedWork W2061956950 @default.
• W4308382016 hasRelatedWork W2066993659 @default.
• W4308382016 hasRelatedWork W2078517976 @default.
• W4308382016 hasRelatedWork W2081460943 @default.
• W4308382016 hasRelatedWork W2091594406 @default.
• W4308382016 hasRelatedWork W4252441337 @default.
• W4308382016 hasRelatedWork W991481628 @default.
• W4308382016 isParatext "false" @default.
• W4308382016 isRetracted "false" @default.
• W4308382016 workType "article" @default.